Table of Contents

Challenges in Polymer Therapeutics.- Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS.- PEG-Adenosine Deaminase and PEG-Asparaginase.- Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C.- PEG-Methioninase.- Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate.- HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer.- Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer.- CM-Dextran-Polyalcohol-Camptothecin Conjugate.- Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs.- An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer.- Polymer Conjugates for Imaging.- S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics.